-
Mashup Score: 121FDA’s Latest Appointment Is … Interesting - 4 day(s) ago
Those of us who follow infectious diseases and vaccine science closely (OK, obsessively) know that the FDA’s Center for Biologics Evaluation and Research (CBER) plays an enormous role in public health. Vaccines, gene therapies, monoclonal antibodies, blood products — all pass through CBER on their path to approval. During the COVID-19 pandemic, this center became […]
Source: blogs.jwatch.orgCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 121FDA’s Latest Appointment Is … Interesting - 5 day(s) ago
Those of us who follow infectious diseases and vaccine science closely (OK, obsessively) know that the FDA’s Center for Biologics Evaluation and Research (CBER) plays an enormous role in public health. Vaccines, gene therapies, monoclonal antibodies, blood products — all pass through CBER on their path to approval. During the COVID-19 pandemic, this center became […]
Source: blogs.jwatch.orgCategories: General Medicine News, Infectious DiseaseTweet-
The new head of FDA’s CBER, @VPrasadMDMPH, is undoubtedly brilliant. He'll oversee vaccines, gene Rx, monoclonal Abs, & blood products. Let's hope he can get along well enough with others to be an effective leader -- the stakes are pretty darn high! https://t.co/jD8JtAjWM4
-
-
Mashup Score: 121FDA’s Latest Appointment Is … Interesting - 5 day(s) ago
Those of us who follow infectious diseases and vaccine science closely (OK, obsessively) know that the FDA’s Center for Biologics Evaluation and Research (CBER) plays an enormous role in public health. Vaccines, gene therapies, monoclonal antibodies, blood products — all pass through CBER on their path to approval. During the COVID-19 pandemic, this center became […]
Source: blogs.jwatch.orgCategories: General Medicine News, Infectious DiseaseTweet-
The new head of FDA’s CBER, @VPrasadMDMPH, is undoubtedly brilliant. He'll oversee vaccines, gene Rx, monoclonal Abs, & blood products. Let's hope he can get along well enough with others to be an effective leader -- the stakes are pretty darn high! https://t.co/jD8JtAjWM4
-
-
Mashup Score: 103On-Service ID Link-o-Rama -- Osmosis Edition - 12 day(s) ago
First-year ID fellows this time of year bring a lot to inpatient consult rotations. Years of high-volume inpatient care have sharpened their clinical instincts, and at this point they have an impressive fund of ID knowledge. Plus, the fellow on our current rotation gets along great with everyone — patients and consulting clinicians alike — […]
Source: blogs.jwatch.orgCategories: General Medicine NewsTweet-
TB rule outs, Abx allergies, CMV, MSSA (of course), and more. Studies sent to an awesome ID fellow during 2 weeks of service — organized for subconscious absorption. 🧠 Link-o-Rama: Osmosis Edition https://t.co/3nGLkJ43Vq
-
-
Mashup Score: 103On-Service ID Link-o-Rama -- Osmosis Edition - 12 day(s) ago
First-year ID fellows this time of year bring a lot to inpatient consult rotations. Years of high-volume inpatient care have sharpened their clinical instincts, and at this point they have an impressive fund of ID knowledge. Plus, the fellow on our current rotation gets along great with everyone — patients and consulting clinicians alike — […]
Source: blogs.jwatch.orgCategories: General Medicine NewsTweet-
TB rule outs, Abx allergies, CMV, MSSA (of course), and more. Studies sent to an awesome ID fellow during 2 weeks of service — organized for subconscious absorption. 🧠 Link-o-Rama: Osmosis Edition https://t.co/3nGLkJ43Vq
-
-
Mashup Score: 164SNAP Trial Helps Resolve Long-Running Controversies Over Management of Staph Bacteremia - 21 day(s) ago
For those who do hospital-based patient care, the significance of Staphylococcus aureus bacteremia (SAB) cannot be overstated. It’s one of the most frequent reasons for infectious disease consultations — and for good reason: when mismanaged or complicated, it can lead to high morbidity, a myriad of complications, and a disturbingly high mortality rate. Despite its clinical […]
Source: blogs.jwatch.orgCategories: General Medicine NewsTweet-
The SNAP trial may finally resolve some of the longest-running debates in SAB management (cefazolin vs semi-synthetic PCN? Is PCN really active vs PSSA?). Congrats to @syctong @Josh_S_Davis, and the global team who made this ambitious trial happen. https://t.co/n8ZXrqrRM6
-
-
Mashup Score: 142SNAP Trial Helps Resolve Long-Running Controversies Over Management of Staph Bacteremia - 24 day(s) ago
For those who do hospital-based patient care, the significance of Staphylococcus aureus bacteremia (SAB) cannot be overstated. It’s one of the most frequent reasons for infectious disease consultations — and for good reason: when mismanaged or complicated, it can lead to high morbidity, a myriad of complications, and a disturbingly high mortality rate. Despite its clinical […]
Source: blogs.jwatch.orgCategories: General Medicine NewsTweet-
The SNAP trial may finally resolve some of the longest-running debates in SAB management (cefazolin vs semi-synthetic PCN? Is PCN really active vs PSSA?). Congrats to @syctong @Josh_S_Davis, and the global team who made this ambitious trial happen. https://t.co/n8ZXrqrRM6
-
-
Mashup Score: 15Looking Back at a Defunct ID Meeting -- and Ahead to a Thriving One - 1 month(s) ago
Back in prehistoric times, many ID doctors and microbiologists would gather each fall at a meeting to review the latest antimicrobial clinical trials and promising “bug-drug” studies of novel compounds in development. The meeting was called the Interscience Conference on Antimicrobial Agents and Chemotherapy, abbreviated ICAAC. There were a bunch of problems with ICAAC. First, […]
Source: blogs.jwatch.orgCategories: General Medicine NewsTweet-
Remember ICAAC? Bad name, weirder pronunciation ("ick-kack"), and a classic case study in conference identity crisis. A look back—and where the big ID trials land now, which is @ESCMID Global. Following closely! #IDSky https://t.co/jAeZmRO3m4
-
-
Mashup Score: 78Gepotidacin -- New Antibiotic or Rare Tropical Bird? - 1 month(s) ago
Imagine you’re birdwatching in the Costa Rican rainforest, Merlin app in hand. A flash of iridescent blue catches your eye. You scan the canopy and whisper excitedly: Look, it’s the elusive Blujepa! A rare sighting! No, not a real bird, but Blujepa is the brand name of gepotidacin, something rarer — and arguably more exciting […]
Source: blogs.jwatch.orgCategories: General Medicine News, HIV/AIDSTweet-
Latest post on a new antibiotic, gepotidacin, which has a novel mechanism of action, is the first new drug for uncomplicated UTIs in decades, and has a brand name that sounds a lot like a tropical bird. Plus some digressions on prog rock, for no reason. https://t.co/CLkO65yo3O
-
-
Mashup Score: 77Gepotidacin -- New Antibiotic or Rare Tropical Bird? - 1 month(s) ago
Imagine you’re birdwatching in the Costa Rican rainforest, Merlin app in hand. A flash of iridescent blue catches your eye. You scan the canopy and whisper excitedly: Look, it’s the elusive Blujepa! A rare sighting! No, not a real bird, but Blujepa is the brand name of gepotidacin, something rarer — and arguably more exciting […]
Source: blogs.jwatch.orgCategories: General Medicine News, HIV/AIDSTweet-
Latest post on a new antibiotic, gepotidacin, which has a novel mechanism of action, is the first new drug for uncomplicated UTIs in decades, and has a brand name that sounds a lot like a tropical bird. Plus some digressions on prog rock, for no reason. https://t.co/CLkO65yo3O
-
The new head of FDA’s CBER, @VPrasadMDMPH, is undoubtedly brilliant. He'll oversee vaccines, gene Rx, monoclonal Abs, & blood products. Let's hope he can get along well enough with others to be an effective leader -- the stakes are pretty darn high! https://t.co/jD8JtAjWM4